biopharma-reporter3h
Setback for Inhibikase Parkinson’s therapy
Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.
biopharma-reporter8h
Atalanta Therapeutics raises $97 million to advance RNAi therapies for CNS disorders
The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...
biopharma-reporter2d
Akero Therapeutics succeeds with MASH liver treatment at phase 2
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
biopharma-reporter2d
Roche’s Elevidys demonstrates significant benefits for DMD patients in Phase 3
The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...
biopharma-reporter7d
Viralgen and Axovia collaborate to manufacture gene therapy for rare disease vision loss
Axovia’s lead program AXV101 is an adeno-associated virus (AAV9)-based investigational gene therapy that aims to slow down or ...
biopharma-reporter7d
Amylyx Pharmaceuticals gets FDA go ahead for phase 1 ALS trial
The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...
biopharma-reporter9d
Neogap Therapeutics move into clinic with personalized cancer immunotherapy
The Swedish biotech hopes its precision therapy will help patients with advanced solid tumors who currently have few ...
biopharma-reporter9d
Nanobiotix’s radiotherapy-activated nanoparticle cancer candidate enters Phase 2
The French biotech company Nanobiotix announced today that it has dosed the first patient in the CONVERGE study, a Phase 2 ...